Patents Examined by Karen I. Krupen
  • Patent number: 4923803
    Abstract: The galactitol level in the body fluid, e.g. blood or urine, is determined by the method that comprises allowing a body fluid sample to contact in vitro with a bacterium capable of producing D-tagatose from galactitol, and measuring the D-tagatose. Such bacterium is of the genus Arthrobacter, specifically, Arthrobacter globiformis ST-48 FERM P-7592 or its mutant, or of the genus Pseudomonas. The method is useful for detecting galactose dysbolism.
    Type: Grant
    Filed: August 8, 1988
    Date of Patent: May 8, 1990
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Ken Izumori, Shuzo Sakai
  • Patent number: 4916081
    Abstract: An immunoassay method and apparatus includes the vibration of beads within a cell, the beads having a complex of a substance conjugated with an enzyme as a marker on the surface thereof, and using an optical measurement device to quantatively determine the amount of the marker in the cell. The vibration is provided by including a magnetic material in the beads and causing a magnetic field to move within the cell. The vibrations have at least a component transverse to a measurement direction of the optical measurement device. The movement of the magnetic field in the cell is caused by the reciprocation of a bar having magnets thereon and in a position adjacent to the cell.
    Type: Grant
    Filed: July 6, 1987
    Date of Patent: April 10, 1990
    Assignee: Toyo Soda Manufacturing Co., Ltd.
    Inventors: Satoru Kamada, Shuji Iwasaki
  • Patent number: 4913883
    Abstract: The degree of agglutination is measured in a magnetic manner instead of optical manner. Microparticles are composed of a magnetic material and the agglutinated condition is measured using a magnetometer. The sizes and distribution of agglutinated materials formed by the antigen-antibody coupling reaction can be correctly measured without affected by light-scattering materials such as proteins or blood cells contained in the specimen, or by absorbant such as pigment, or by fluorescent material. Therefore, the concentration of antigen is measured maintaining high precision.
    Type: Grant
    Filed: July 20, 1988
    Date of Patent: April 3, 1990
    Assignee: Hitachi, Ltd.
    Inventors: Kazumichi Imai, Daizo Tokinaga, Koichi Yokosawa
  • Patent number: 4897354
    Abstract: Disclosed herein is a P. falciparum merozoite antigenic polypeptide of approximate molecular weight 185,000. The polypeptide and processing fragments are specific to, and isolable using, a monoclonal antibody produced by hybridoma cell line HB 9148. The polypeptides are useful in immunizing against malaria.
    Type: Grant
    Filed: July 28, 1986
    Date of Patent: January 30, 1990
    Assignee: University of Hawaii
    Inventor: Wasim A. Siddiqui
  • Patent number: 4889922
    Abstract: A monoclonal antibody is disclosed which is specific for human colon fibroblast-derived tissue plasminogen activator (t-PA), and which is useful for immunoaffinity chromatography purification of t-PA and determination of t-PA in a biological sample.
    Type: Grant
    Filed: January 6, 1989
    Date of Patent: December 26, 1989
    Assignee: Monsanto Co.
    Inventors: Jon P. Schaumann, Jitka V. Olander, Nicholaos K. Hrakas, Joseph Feder
  • Patent number: 4883752
    Abstract: Disclosed is a monoclonal antibody to HBsAg which is prepared by forming hybridomas between human peripheral blood lymphocyte cells, derived from humans having high titers of anti-HBsAg, and myeloma cells, cloning the hybridomas and selecting the antibody-producing clones. The monoclonal antibody can react with all the subtypes of HBsAg and is expected to be very effective in diagnosis and treatment of diseases due to the viral infection.
    Type: Grant
    Filed: October 24, 1985
    Date of Patent: November 28, 1989
    Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Yasuyuki Eda, Toshihiro Maeda, Kiyoto Nishiyama, Akira Tashiro
  • Patent number: 4879225
    Abstract: A method for enhancing production of antibodies through immunization with insolubilized immune complexes is disclosed. Purified antigen or heterogeneous antigen mixtures may be combined with polyclonal or monoclonal antibody and the resultant complex bound to insolubilized protein A to form insolubilized immune complexes. Methods for improving the immunogenicity of a soluble antigen and for producing monoclonal anti-idiotypic antibodies are also disclosed. Monoclonal antibodies that are specific for a distinct, as yet unrecognized epitope may be produced by another disclosed method. Insolubilized immune complexes, comprising antigen and antibody that is either directly linked to Sepharose.RTM. or absorbed onto insolubolized protein A, and immunosorbents, comprising antibody absorbed onto insolubilized protein A, are also disclosed.
    Type: Grant
    Filed: March 11, 1987
    Date of Patent: November 7, 1989
    Assignee: NeoRx Corporation
    Inventors: Alton C. Morgan, Jr., Clive S. Woodhouse, Robert F. McIntyre
  • Patent number: 4855225
    Abstract: A method is provided for detecting up to four classes of oligonucleotides which have been separated by gel electrophoresis. The method entails labeling members of each class of oligonucleotide with dyes selected from separate sets of dyes so that members of the same class are labeled with dyes from the same set. The four sets of dyes of the invention consist of derivatives of fluorescein, 2',7'-dimethoxy-4', 5'-dichlorofluorescein, tetramethylrhodamine, and rhodamine X carboxylic or sulfonic acid, respectively. Dyes from these sets are spectrally resolvable under conditions of gel electrophoresis.
    Type: Grant
    Filed: February 7, 1986
    Date of Patent: August 8, 1989
    Assignee: Applied Biosystems, Inc.
    Inventors: Steven Fung, Sam L. Woo, Richard P. Haugland, Steven M. Menchen, Charles R. Connell
  • Patent number: 4853335
    Abstract: A sandwich immunoassay method is disclosed that is useful for the identification of an antigen in biological specimens. The method is comprised of a colloidal gold labeled binder specific for epitopes or receptors of a ligand, nonporous particulate solid phase which have antiligand covalently attached, and which said reagents are combined with the biological specimen or an extract of the biological specimen, and after an appropriate incubation, the said reactant mixture is contacted to a porous film having an exposed surface area of contact no greater than 30 mm.sup.2 to separate and concentrate the particle bound colloidal gold labeled binder from the unbound. The identification of an antigen is determined by the presence of color on the surface of the solid phase particles captured on the surface of the film. A competitive inhibition assay can be also used to identify the presence of a hapten or antigen, in which case the presence of the analyte is determined by the absence of color.
    Type: Grant
    Filed: September 28, 1987
    Date of Patent: August 1, 1989
    Inventors: Duane A. Olsen, David Bernstein
  • Patent number: 4839289
    Abstract: Murine monoclonal antibodies specific to unique antigenic determinants on mammalian terminal deoxynucleotidyl transferases (TdT). The monoclonal antibodies specifically bind to TdT in a wide variety of mammalian cells including human, mouse, rat, rabbit and bovine origin. The monoclonal antibodies are secreted by hybridoma cells derived from fusion of murine plasmacytoma cells with splenocytes from mice immunized with TdT from bovine thymus cells. The monoclonal antibodies can detect small numbers of TdT-positive cells for monitoring of TdT-positive leukemias and lymphomas in multiple species, including human.
    Type: Grant
    Filed: November 26, 1985
    Date of Patent: June 13, 1989
    Assignee: The Board of Regents of the University of Texas System
    Inventor: R. Graham Smith